The T315I mutation is among the most frequently identified BCR::ABL1 mutations, occurring in 2% to 16% of patients with imatinib- or second-generation TKI-resistant CML and increasing in frequency with subsequent lines of therapy [8, 9]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.